Tag: Pml risk

Infusion reactions affect 34% to 40% of patients receiving their first ocrelizumab infusion, raising questions about its safety and whether ocrelizumab is hazardous. This article addresses the common side effects and rare but serious risks associated with this multiple sclerosis medication.

According to MyMSTeam, the general guideline for a Tysabri (natalizumab) washout period is typically one to three months when switching to another disease-modifying therapy. Determining the optimal length of this period requires a careful balance between managing the risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML) and preventing a relapse of the underlying condition.

Over 40% of people receiving Tysabri in the U.S. have been on the medication for over five years, demonstrating its long-term viability for many patients. The decision regarding *how many years can you stay on Tysabri* is not based on a set limit but on an ongoing, individualized assessment of benefit versus risk.